HealthPrep on MSN11mon
How To Treat Hunter SyndromeHunter syndrome is an exceedingly rare genetic disorder caused by a malfunctioning or missing enzyme. Patients with Hunter ...
Hosted on MSN2mon
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy DesignationDenali’s wholly owned program, DNL310 or tividenofusp alfa, is an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase (IDS) replacement therapy in development for MPS II (Hunter syndrome).
Shire’s attempts to develop a drug for cognitive impairment from the rare inherited disease Hunter Syndrome has failed to produce results. The company’s Elaprase (idursulfase) is already ...
This annual observance brings attention to the 300 million people worldwide living with rare diseases, including those impacted by Hunter syndrome. Rare Disease Week, held in conjunction with Rare ...
Feb. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome (MPS II) in the 24-week ...
GC Biopharma announced on the 5th that the Ministry of Food and Drug Safety has designated the treatment for severe Hunter syndrome, 'Hunterase ICV (intracerebroventricular),' as an orphan drug.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results